Asston Pharmaceuticals MD, chairman, board of directors and AGM
BSE: 544445Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹123.94.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹142 Cr3,188th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 29 May 2026
- 274.2
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹3.35 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 36.7
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 29 May 2026
- 1.3%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹3.35 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 9.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 29 May 2026
- −2.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.13
- Volume, BSEVolume. Shares traded on the last trading day.
- 1,19,000
Statutory auditor
Named in the results for the quarter to Mar 2026.
- M/S PANCHAL SK & ASSOCIATESPeer-review certificate valid to Sep 2027
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Asston Pharmaceuticals AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Asston Pharmaceuticals share news and announcements
Annual general meeting, 29 Sep 2026
670 shareholders on the register on 22 Sep 2026; present: 3 promoters and 7 others; votes counted by PRAGYA JAIN / PRAGYA & ASSOCIATES.The company's voting result (opens in a new tab)
To receive, consider and adopt the audited financial statements, i.e., Balance Sheet, the Statement of Profit & Loss account and cash flow statement of the Company for the financial year ended 31st March, 2026 and the Reports of the Auditors and Board of Directors thereonMoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 54.01% · promoters 100.00% · institutions 0.00% · other public 6.79%
- To appoint Mr. Ashish Narayan Sakalkar, (DIN: 06601011) Managing Director of the Company, who retires by rotation as a director and in this regardOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 32.24% · promoters 57.04% · institutions 0.00% · other public 6.79%
- To consider and approve the appointment of M/s Panchal S K & Associates (Peer Review Certificate No. 018089 and Firm Registration No. 145989w) as statutory auditors of the CompanyOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 54.01% · promoters 100.00% · institutions 0.00% · other public 6.79%
- To consider and approve an increase in remuneration of Mr. Ashish Narayan Sakalkar (DIN: 06601011), Managing Director of the CompanySpecialPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 3.35% · promoters 0.00% · institutions 0.00% · other public 6.79%
- To consider and approve an increase in remuneration of Mrs. Saili Jayaram More Din 02691527, Whole Time Director and CEO of the CompanySpecialPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 3.35% · promoters 0.00% · institutions 0.00% · other public 6.79%
- To consider and approve an increase in remuneration of Mr. Sachin Chandrakant Badakh, DIN 08685214, non-executive director of the CompanySpecialPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 3.35% · promoters 0.00% · institutions 0.00% · other public 6.79%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
How money raised was used
Reported for the quarter to Mar 2026.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere | Spent elsewhere, amount |
|---|---|---|---|---|---|---|
| Public IssuesJul 2025 | 27.56 | Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit | 6.00 | 6.00 | No | |
| Public IssuesJul 2025 | 27.56 | Funding the incremental working capital requirements of our Company | 13.00 | 13.00 | No | |
| Public IssuesJul 2025 | 27.56 | Repayment and/or prepayment, in part or full, of certain of our outstanding borrowings availed by our Company | 1.00 | 1.00 | No | |
| Public IssuesJul 2025 | 27.56 | General Corporate Purposes | 3.96 | 3.96 | No | 0.01 |
| Public IssuesJul 2025 | 27.56 | IPO expenses | 3.60 | 3.60 | No | 0.01 |